Skip to main content
Explore URMC

Haoming Qiu, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

Appointment: (585) 396-6180

Office: (585) 275-5625

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Radiation Oncology


Professional Background

Dr. Haoming (Carl) Qiu is a radiation oncologist at the University of Rochester Medical Center seeing patients at both Wilmot Cancer Center in Rochester and Sands Cancer Center in Canandaigua. Dr. Qiu received his medical education at the Johns Hopkins University School of Medicine in Baltimore, MD and completed his residency in radiation oncology at the University of Rochester Medical Center. Dr. Qiu brings a high level of technical expertise along with a friendly and optimistic attitude in caring for his patients.

Dr. Qiu also provides Lutathera (lutetium Lu 177 dotatate) PRRT (Peptide Receptor Radionuclide Therapy) for patients with neuroendocrine tumors. If you are interested in a consultation, please have your doctor call our office for a referral. (585) 275-5625.


Dr. Qiu's research is focused on the use of radiation therapy in the treatment of gastrointestinal and lung cancers with a special focus on the use of stereotactic body radiotherapy (SBRT) to deliver ablative doses of radiation with high levels of precision and conformality.. Dr. Qiu also directs the palliative radiation service at URMC, providing treatments aimed at alleviating symptoms for patients with advanced cancers

Dr. Qiu is the author of several peer reviewed articles and has presented his research at numerous national and international meetings in oncology.



  • Radiation Oncology - American Board of Radiology


MD | Johns Hopkins Hospital

Post-doctoral Training & Residency

07/01/2013 - 06/30/2016
Residency in Radiation Oncology at University of Rochester Medical Center

07/02/2012 - 06/30/2013
Residency in Radiation Oncology at Loyola University Medical Center

06/23/2011 - 06/22/2012
Internship in Internal Medicine at Sinai Hospital of Baltimore

VIEW ALL expand_more


Roentgen Resident/Fellow Research Award
Sponsor: RSNA Research and Education Foundation
Location: University of Rochester Medical Center

Excellence in Medical Student Research
Location: Johns Hopkins University School of Medicine

Clinical Trials

A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Lead Researcher: Haoming Qiu

Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.

View Study Details


Journal Articles

Michael T Milano, James E Bates, Justin Budnik, Haoming Qiu, Sara Hardy, Michael A Cummings, Megan A Baumgart, Ronald J Maggiore, Deborah A Mulford & Kenneth Y Usuki. "Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis". Lung Cancer Management. 2020; .

Milano MT, Mihai A, Kang J, Singh DP, Verma V, Qiu H, Chen Y, Kong FS. "Stereotactic body radiotherapy in patients with multiple lung tumors: a focus on lung dosimetric constraints." Expert review of anticancer therapy.. 2019 Nov 5; :1-11. Epub 2019 Nov 05.

Mills BN, Connolly KA, Ye J, Murphy JD, Uccello TP, Han BJ, Zhao T, Drage MG, Murthy A, Qiu H, Patel A, Figueroa NM, Johnston CJ, Prieto PA, Egilmez NK, Belt BA, Lord EM, Linehan DC, Gerber SA. "Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment." Cell reports.. 2019 Oct 8; 29(2):406-421.e5.